

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

UTSD:521/WIM

Serial No.

09/112,041

Applicant

Maria-Ana Ghetie et al.

Filing Date:

July 8, 1998

Group:

1642

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1						

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
ON	B1						

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
ON	C66	Caron <i>et al.</i> , "Engineered humanized dimeric forms of IgG are more effective antibodies," <i>J. Exp. Med.</i> , 176:1191-1195, Oct. 1992.
ON	C67	Hudson, "Recombinant antibody constructs in cancer therapy," <i>BioTechnology</i> , 12:548-555, July 1994.
ON	C68	Mota <i>et al.</i> , "Preparation and some properties of dimeric rabbit IgG antibody," <i>Mol. Immunol.</i> , 21(7):641-645, 1984.
ON	C69	Shopes, "A genetically engineered human IgG mutant with enhanced cytolytic activity," <i>Mol. Immunol.</i> , 148(9):2918-2922, May 1992.
ON	C70	Shuford <i>et al.</i> , "Effect of light chain V region duplication on IgG oligomerization and in vivo efficacy," <i>Science</i> , 252(5006):724-7, May 1991.
ON	C71	Smith and Morrison, "Recombinant polymeric IgG: an approach to engineering more potent antibodies," <i>BioTechnology</i> , 12:683-688, July 1994.
ON	C72	Smith <i>et al.</i> , "Addition of a $\mu$ -tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytotoxicity by IgG4," <i>J. Immunol.</i> , 154:2226-2236, 1995.
ON	C73	Wolff <i>et al.</i> , "Monoclonal antibody homodimers: enhanced antitumor activity in nude mice," <i>Can. Res.</i> , 53:2560-2565, June 1993.

EXAMINER:

Jennifer Nichols

DATE CONSIDERED:

1/16/2000

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

List of Patents and Publications for Applicant  
 INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



Atty. Docket No.

UTSD:521/WIM

Serial No.

09/112,041

Applicant

Maria-Ana Ghetie et al.

Filing Date:

July 8, 1998

Group:

1642

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C74	Wolff <i>et al.</i> , "Human monoclonal antibody homodimers: effect of valency on in vitro and in vivo antibacterial activity," <i>J. Immunol.</i> , 148(8):2469-2474, April 1992.

EXAMINER:

Jennifer Nichols

DATE CONSIDERED:

1/16/2000

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

**Form PTO-1449** (modified)

Atty. Docket No.

Serial No.

UTSD:521/WIM

09/112,041

U.S. Department of Patents and Publications for Applicant's

Applicants

Maria-Ana Ghetie, Jonathan W. Uhr  
and Ellen S. Vitetta**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Filing Date:

July 8, 1998

Group:

1643

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

**U.S. Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date if App.

**Foreign Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
1	B1	WO 92/04053	03/19/92	PCT	—	—	—

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
1	C1	Adair, "Engineering antibodies for therapy," <i>Immunol. Rev.</i> , 192; 130:5-40, 1992.
2	C2	Akiyama <i>et al.</i> , "Fibronectin and integrins in invasion and metastasis," <i>Cancer Metastasis Rev.</i> , 14:173-189, 1995.
3	C3	Beckwith <i>et al.</i> , "Anti-IgM mediated growth inhibition of a human B-lymphoma cell line is independent of phosphatidylinositol turnover and protein kinase C activation and involves tyrosine phosphorylation," <i>J. Immunol.</i> , 147:2411-2418, 1991.
4	C4	Bridges <i>et al.</i> , "Selective <i>in vivo</i> antitumor effect of monoclonal anti-I-A antibody on B cell lymphoma," <i>J. Immunol.</i> , 139:4242-4249, 1987.
5	C5	Brown <i>et al.</i> , "Antiidiotype antibody therapy of B-cell lymphoma," <i>Semin. Oncol.</i> , 16:199-210, 1989.
6	C6	Brunner <i>et al.</i> , "Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas," <i>Nature</i> , 373:441-444, 1995.
7	C7	Caron <i>et al.</i> , "Engineered humanized dimeric forms of IgG are more effective antibodies", <i>J. Exp. Med.</i> , 176:1191-1195, 1992.
8	C8	Cumber <i>et al.</i> , "Comparative stabilities in vitro and in vivo of a recombinant mouse antibody FvCys fragment and a bisFvCys conjugate," <i>J. Immunol.</i> , 149(1):120-126, 1992.

Examiner:

Jennifer Nichols

Date Considered:

1/16/2000

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)

**Form PTO-1449** (modified)

Atty. Docket No.

UTSD:521/WIM

Serial No.

09/112,041

List of Patents and Publications for Applicant's

**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicants

Maria-Ana Ghetie, Jonathan W. Uhr  
and Ellen S. Vitetta

Filing Date:

July 8, 1998

Group:

1643

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C9	Denkers <i>et al.</i> , "Influence of antibody isotype of passive serotherapy of lymphoma," <i>J. Immunol.</i> , 135:2183-2186, 1995.
	C10	Dhein <i>et al.</i> , "Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)," <i>Nature</i> , 373:438-441, 1995.
	C11	Dillman, "Antibodies a cytotoxic therapy," <i>J. Clin. Oncol.</i> , 12(7):1497-1515, 1994.
	C12	Dyer <i>et al.</i> , "Effects of CAMPATH-1 antibodies <i>in vivo</i> in patients with lymphoid malignancies: Influence of antibody isotype," <i>Blood</i> , 73:1431-1439, 1989.
	C13	Edward, "Integrins and other adhesion molecules involved in melanocytic tumor progression," <i>Curr. Opin. Oncol.</i> , 7:185-191, 1995.
	C14	Funakoshi <i>et al.</i> , "Inhibition of human B-cell lymphoma growth by CD40 stimulation," <i>Blood</i> , 83:2787-2794, 1994.
	C15	Ghetie <i>et al.</i> , "The use of immunoconjugates in cancer therapy," <i>Exp. Opin. Invest. Drugs.</i> , 5(3):309-321, 1996.
	C16	Ghetie <i>et al.</i> , "Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for <i>in vivo</i> therapy," <i>Cancer Res.</i> , 48:2610-2617, 1988.
	C17	Ghetie <i>et al.</i> , "Anti-CD19 inhibits the growth of human B-cell tumor lines <i>in vitro</i> and of Daudi cells in SCID mice by inducing reversible cell cycle arrest," <i>Blood</i> , 83:1329-1336, 1994.
	C18	Ghetie <i>et al.</i> , "Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma," <i>Int. J. Cancer</i> , 68:93-96, 1996.
	C19	Ghetie <i>et al.</i> , "Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice," <i>Int. J. Cancer</i> , 45:481-485, 1990.
	C20	Ghetie <i>et al.</i> , "The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond," <i>J. Immunol. Methods</i> , 142:223-230, 1991.
	C21	Ghetie <i>et al.</i> , "Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail," <i>Blood</i> , 84:702-707, 1994.

Examiner:

*Jennifer Nichols*

Date Considered:

*1/18/2000*

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)

**Form PTO-1449** (modified)

Atty. Docket No.

Serial No.

UTSD:521/WIM

09/112,041

List of Patents and Publications for Applicant's

Applicants

Maria-Ana Ghetie, Jonathan W. Uhr  
and Ellen S. Vitetta**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Filing Date:

July 8, 1998

Group:

1643

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
(22)	C22	Ghetie <i>et al.</i> , "The anti-tumor activity of an anti-CD22-immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin," <i>Blood</i> , 80:2315-2320, 1992.
(22)	C23	Greenwood <i>et al.</i> , "Engineering multiple-domain forms of the therapeutic antibody CAMPATH-IH: Effects on complement lysis", <i>Therap. Immunol.</i> , 1:247-255, 1994.
(22)	C24	Guo <i>et al.</i> , "Inhibition of human melanoma growth and metastasis in vivo by anti-CD44 monoclonal antibody," <i>Cancer Res.</i> , 54:1561-1565, 1994.
(22)	C25	Hale <i>et al.</i> , "Therapeutic potential of rat monoclonal antibodies: Isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes," <i>J. Immunol.</i> , 134:3056-3061, 1985.
(22)	C26	Hale <i>et al.</i> , "Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody," <i>Lancet</i> , 2:1394-1399, 1988.
(22)	C27	Hamblin <i>et al.</i> , "Preliminary experience in treating lymphocytic leukaemia with antibody to immunoglobulin idiotypes on the cell surfaces," <i>Br. J. Cancer</i> , 42:495-502, 1980.
(22)	C28	Hamblin <i>et al.</i> , "Initial experience in treating human lymphoma with a chimeric univalent derivative of monoclonal anti-idiotypic antibody," <i>Blood</i> , 69:790-797, 1987.
(22)	C29	Hekman <i>et al.</i> , "Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody," <i>Cancer Immunol., Immunother.</i> , 32:364-372, 1991.
(22)	C30	Herlyn and Koprowski, "IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells," <i>Proc. Natl. Acad. Sci. USA</i> , 79:4761-4765, 1982.
(22)	C31	Hooijberg <i>et al.</i> , "Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model," <i>Cancer Res.</i> , 55(4):840-846, 1995.
(22)	C32	Hooijberg <i>et al.</i> , "Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2," <i>Cancer Res.</i> , 55(12):2627-2634, 1995.
(22)	C33	Ju <i>et al.</i> , "Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation," <i>Nature</i> , 373:444-448, 1995.
(22)	C34	Kaminski <i>et al.</i> , "Importance of antibody isotype in monoclonal anti-idiotypic therapy of a murine B-cell lymphoma," <i>J. Immunol.</i> , 136:1123-1130, 1986.

Examiner:

Jennifer Nichols

Date Considered:

1/14/2000

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)

**Form PTO-1449** (modified)

Atty. Docket No.

Serial No.

UTSD:521/WIM

09/112,041

List of Patents and Publications for Applicant's

Applicants

Maria-Ana Ghetie, Jonathan W. Uhr  
and Ellen S. Vitetta**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Filing Date:

July 8, 1998

Group:

1643

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
(M)	C35	Kaminski <i>et al.</i> , "Radioimmuno-therapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody," <i>N. Engl. J. Med.</i> , 329:459-465, 1993.
(M)	C36	Marches <i>et al.</i> , "Tumor dormancy and cell signaling III: Role of hypercrosslinking of IgM and CD40 on the induction of cell cycle arrest and apoptosis in B lymphoma cells," <i>Therap. Immunol.</i> , 2:125-136, 1996.
(M)	C37	Meeker <i>et al.</i> , "A clinical trial of anti-idiotypic therapy for B cell malignancy," <i>Blood</i> , 65:1349-1363, 1985.
(M)	C38	Page and Defranco, "Role of phosphoinositide-derived second messengers in mediated anti-IgM-induced growth arrest of WEHI-231 B lymphoma cells," <i>J. Immunol.</i> , 140:3717-26, 1988.
(M)	C39	Press <i>et al.</i> , "Monoclonal antibody 1 F5 (anti-CD20) serotherapy of human B cell lymphomas," <i>Blood</i> , 69:584-591, 1987.
(M)	C40	Press <i>et al.</i> , "Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support," <i>N. Engl. J. Med.</i> , 329:1219-1224, 1993.
(M)	C41	Qi <i>et al.</i> , "Antibody-targeted lymphokine-activated killer cells inhibit liver micrometastases in severe combined immunodeficient mice," <i>Gastroenterology</i> 109(6):1950-1957, 1995.
(M)	C42	Racila <i>et al.</i> , "Tumor dormancy and cell signaling: Anti- $\mu$ -induced apoptosis in human B-lymphoma cells is not caused by an APO-1 - APO-1 ligand interaction," <i>Proc. Natl. Acad. Sci., USA</i> , 93:2165-2168, 1996.
(M)	C43	Racila <i>et al.</i> , "Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice," <i>J. Exp. Med.</i> , 181:1539-1550, 1995.
(M)	C44	Rankin <i>et al.</i> , "Treatment of two patients with B-cell lymphoma with monoclonal anti-idiotypic antibodies," <i>Blood</i> , 65:1373-1381, 1985.
(M)	C45	Riethmüller <i>et al.</i> , "Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma," <i>Lancet</i> 343:1174-1177, 1994.
(M)	C46	Schreiber <i>et al.</i> , "An unmodified anticarcinoma antibody, BR96, localizes to and inhibits the outgrowth of human tumors in nude mice," <i>Cancer Res.</i> , 52:3262-3266, 1992.

Examiner:

Jennifer Nichols

Date Considered:

1/16/2000

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)

**Form PTO-1449** (modified)

Atty. Docket No.

UTSD:521/WIM

Serial No.

09/112,041

List of Patents and Publications for Applicant's

Applicants

Maria-Ana Ghetie, Jonathan W. Uhr  
and Ellen S. Vitetta**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Filing Date:

July 8, 1998

Group:

1643

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C47	Scott <i>et al.</i> , "Lymphoma models for B-cell activation and tolerance. II. Growth inhibition by anti-m of WEHI-231 and the selection and properties of resistant mutants", <i>Cell Immunol.</i> , 93:124-131, 1985.
	C48	Scott <i>et al.</i> , "T cells commit suicide, but B cells are murdered," <i>J. Immunol.</i> , 156:2352-2356, 1996.
	C49	Shopes, "A genetically engineered human IgG mutant with enhanced cytolytic activity," <i>J. Immunol.</i> , 148(9):2918-2922, 1992.
	C50	Shuford <i>et al.</i> , "Effect of light chain V region duplication on IgG oligomerization and <i>in vivo</i> efficacy", <i>Science</i> 252:724-727, 1991.
	C51	Smith and Morrison, "Recombinant polymeric IgG: An approach to engineering more potent antibodies", <i>Bio/Technol.</i> , 12:683-688, 1994.
	C52	Trauth <i>et al.</i> , "Monoclonal antibody-mediated tumor regression by induction of apoptosis," <i>Science</i> , 245:301-305, 1989.
	C53	Vitetta and Uhr, "Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy," <i>Cancer Res.</i> , 54:5301-5309, 1994.
	C54	Wolff <i>et al.</i> , "Human monoclonal antibody homodimers", <i>J Immunol.</i> , 148:2469-2474, 1992.
	C55	Wolff <i>et al.</i> , "Monoclonal antibody homoconjugates: Enhanced antitumor activity in nude mice", <i>Cancer Res.</i> , 53:2560-2565, 1993.
	C56	Yefenof <i>et al.</i> , "Cancer dormancy: Isolation and characterization of dormant lymphoma cells," <i>Proc. Natl. Acad. Sci., USA</i> , 90:1829-1833, 1993.
	C57	Zahalka <i>et al.</i> , "Lymph node (but not spleen) invasion by murine lymphoma is both CD44- and hyaluronate-dependent," <i>J. Immunol.</i> , 154:5345-5355, 1995.

Examiner:

*Jennifer Nichols*

Date Considered:

*1/16/2000*

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)

**Form PTO-1449** (modified)

Atty. Docket No.

Serial No.

UTSD:521/WIM

09/112,041

List of Patents and Publications for Applicant's

Applicants

Maria-Ana Ghetie, Jonathan W. Uhr  
and Ellen S. Vitetta**INFORMATION DISCLOSURE STATEMENT**

Filing Date:

Group:

July 8, 1998

1643

(Use several sheets if necessary)

U.S. Patent Documents

Foreign Patent Documents

Other Art

See Page 1

See Page 1

See Page 1

**U.S. Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date if App.
	A1	5,686,072	11/11/97	Uhr <i>et al.</i>	—	—	—

**Foreign Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
②	B2	EP 0468637	01/29/92	Europe	—	—	—
②	B3	EP 0453082	10/23/91	Europe	—	—	—
②	B4	EP 0404097	12/27/90	Europe	—	—	—
②	B5	WO 91/03493	03/21/91	PCT	—	—	—

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
②	C63	International Search Report dated January 15, 1999 (PCT/US98/14222)(UTFD:521P).
②	C64	Kita <i>et al.</i> , "ERBB receptor activation, cell morphology changes, and apoptosis induced by anti-HER2 monoclonal antibodies," <i>Biochem. Biophys. Res. Comm.</i> , 226(1):59-69, 1996.
②	C65	Wu <i>et al.</i> , "Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin," <i>J. Clin. Invest.</i> , 95(4):1897-1905, 1995.

Examiner: *Jenni for Nichols*

Date Considered:

*1/16/2000*

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)



**Form PTO-1449** (modified)

Atty. Docket No.

UTSD:521/WIM

Serial No.

09/112,041

List of Patents and Publications for Applicant's

Applicants

Maria-Ana Ghetie, Jonathan W. Uhr  
and Ellen S. Vitetta

Filing Date:

July 8, 1998

Group:

1643

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1






**U.S. Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date if App.

**Foreign Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C58	Hellström <i>et al.</i> , "Immunoconjugates and Immunotoxins for Therapy of Carcinomas," <i>Adv. Pharmacol.</i> , 33:349-388, 1995.
	C59	Levy and Miller, "Therapy of lymphoma directed at idiotypes", <i>J. Natl. Cancer Inst. Monographs</i> , 10:61-68, 1990.
	C60	Morrison and Oi, "Genetically engineered antibody molecules," <i>Adv. Immunol.</i> , 44:65-91, 1989.
	C61	Ruiz <i>et al.</i> , "Suppression of mouse melanoma metastasis by EA-1, a monoclonal antibody specific for $\alpha_6$ integrins," <i>Cell Adhes. Commun.</i> , 1:67-81, 1993.
	C62	Waldmann, "Immune receptors: Targets for therapy of leukemia/lymphoma, autoimmune diseases and for the prevention of allograft rejection," <i>Annu. Rev. Immunol.</i> , 10:675-704, 1992.

Examiner:

*Jennifer Nichols*

Date Considered:

*1/16/2000*

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.